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peripheral blood upon recovery of neutrophils. If peripheral
blood CD34 count was below 10/microL, Plerixafor 0.24 mg/
kg/day with or without Neupogen 10mcg/kg/day was added.
Absolute pre CD34 values prior to Plerixafor ranged from
0e6. Pre CD34 values after Plerixafor ranged from 6 - 303.
Target CD34 yield per kg for NHL/HL patients was 2-5 X 106.
Target CD34 yield per kg for MM patients was 5-10 X 106.
Following this intervention 11 patients were able to
successfully complete stem cell mobilization and achieve
target yields. 2 MM patients did not meet the collection goal
for 2 transplants but did have sufﬁcient yield for one. Median
total CD34 yield per kg was 6.9 X 106. Mean total CD34 yield
for NHL/HL pts was 6.17 X 106 per kg. Mean total CD34 yield
for MMpts was 10.59 X 106 per kg. Mean total MNC yield was
14.23 X 108 per kg for NHL/HL pts. Mean total MNC yield was
8.71 X 108 per kg for MM pts. Average time for neutrophil
engraftment was 11.46 days. Average time for platelet
engraftment was 19.91 days. There were no major compli-
cations associated with the above combination and no
unanticipated side effects.
Combination of Plerixafor and Filgrastim can be safely and
successfully administered to patients with inadequate
peripheral blood pre-CD34 counts following chemotherapy
based mobilization regimens. This will prevent delay in the
transplantation process.131
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Background: Over 400 cases of pediatric severe aplastic
anemia (SAA) occur annually in the United States. A growing
number of children with SAA may have had their stem cells
harvested through cord blood collection. We describe a 9-
year-old male with SAA treated successfully with an autol-
ogous cord blood transplant following immunoablative
chemotherapy. With increasing numbers of cord blood
cryopreservations, the use of autologous cord blood in the
treatment of SAA might be considered as initial therapy.
Methods: A previously healthy 9-year-old Hispanic malewas
diagnosed with acquired SAA. Due to ongoing transfusion
support, and the lack of a sibling donor, anti-thymocyte
globulin and cyclosporine was initiated. Six months
following the start of immunosuppressive therapy, the
patient had no marrow recovery. An unrelated bone marrow
donor search revealed one 9 out of 10 matched unrelated
bonemarrow donor (HLA A antigenmismatch). One 10 out of
10 matched cord blood unit was available in the public cord
blood registry and further inquiry revealed that this donated
cord blood unit was an autologous unit. Given the lack of
response to immunosuppressive therapy, the risks associated
with the use of a mismatched unrelated donor hematopoi-
etic cell transplantation (HCT), and the availability of the
patients own cord blood unit, a decision was made to
proceed with autologous cord blood HCT.Results: The HCT preparative regimen included: ﬂudarabine
30 mg/m2/day from Day -6 to Day -4 for a total dose of 90
mg/m2. Cyclophosphamide 60 mg/kg/day was given from
Day -3 to Day -2 for a total dose of 120 mg/kg together with
MESNA prophylaxis. This was followed by a day of rest on
Day -1 and an infusion of 3.0 x 10e7 TNC/kg and 0.9 x 10e6
CD34+ /kg using an autologous cord blood unit on Day 0. His
absolute neutrophil count exceeded 500 cell/uL on Day + 21
and has subsequently remained above this threshold
without growth factor support. His platelet count was
greater than 20,000 /uL on Day + 36 with his last platelet and
packed red blood cell transfusion given on Day +20. The
patient was discharged at Day +27 and remains transfusion
independent at the time of his most recent clinical assess-
ment at Day +100. His Lansky performance status was 100 at
discharge and has remained so now at over 3 months
following transplant.
Conclusion: To our knowledge, this is the ﬁrst description of
a successful application of autologous cord blood HCT in
a pediatric patient with acquired SAA using an immunoa-
blative preparative regimen consisting of ﬂudarabine and
cyclophosphamide. We found autologous cord blood HCT
following an immunoablative combination of ﬂudarabine
and cyclophosphamide to be an effective and safe alternative
to the potential complications as well as morbidity and
mortality associated with the use of matched unrelated
donor HCT or the use of other alternative donor HCT
approaches.132
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Background: Engraftment syndrome (ES), characterized by
noninfectious fever, rash, diarrhea, and/or respiratory
symptoms during engraftment, can be associated with
increased morbidity and resource utilization (e.g., IV antibi-
otics, hospitalization) after autologous stem cell transplant
(ASCT). ES remains a clinical diagnosis, without conﬁrmed
biomarkers or standardized treatment recommendations.
Herein, we describe the clinical, laboratory, and outcomes
data from a large contemporary cohort of ASCT recipients
and suggest new diagnostic criteria.
Methods: 526 consecutive patients who underwent ASCT at
Mayo Clinic from 1/1/2009-12/31/2010 were included.
Diseases included: multiple myeloma, 48%; NHL, 30%;
amyloidosis, 12%; HL, 7%; and POEMS, 2%. Mayo Clinic criteria
for ES was deﬁned by a noninfectious fever of 38.3C from 4d
prior to WBC 500/ul up until ANC 500/ul and at least one of
the following: rash (erythematous with >25% trunk
involvement), diarrhea (>3 loose stools/d), or pulmonary
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consequences were compared for Maiolino and Spitzer
hybrid criteria (Maiolino criteria w/in 4d of ANC500 rather
than 24 hours of ﬁrst neutrophils) and Mayo Criteria (MC).
Pretransplant characteristics, ASCT complications, and the
dynamics of count recovery were all assessed.
Results: 146 (28%) had ES by MC while 48 (9%) had ES by
Maiolino Criteria. Patients with ES by MC experienced longer
hospital stays and received more IV antibiotics (Table 1).
Patients with ES were more likely to have amyloidosis,
a trend toward a higher pre-apheresis PB CD34+ count
(p¼0.053) and pre-apheresis PB WBC count (p¼0.052);
receive fewer days of G-CSF (P < 0.0001), and undergo
fewer apheresis sessions to meet collection goals (p¼0.012)
with more CD34+/kg collected per apheresis (p¼0.012).
They were also less likely to have undergone
chemomobilization. Too few patients perished within 30
days of ASCT (<1%) for meaningful statistical conclusions,
although, 5 patients died within 30d, 3 of whom ES may
have contributed. Patients with ES had shorter times to
ANC500 and ANC1000 (P < 0.0001) as well as from
WBC500 to ANC1000 (P < 0.0001). Patients on
corticosteroids for other reasons had fewer episodes of ES
(4% vs 29%; RR 0.133; P ¼ .003).
Conclusions: Mayo ES criteria were better able to identify
patients with increased resource utilization. As the rate of ES
was signiﬁcantly less in patients on corticosteroids for
reasons other than ES, it is possible that prophylaxis with low
doses of corticosteroids in patients at high risk of ES may















11 8 <0.0001 10 10 0.28
Days hospitalized 6 0 <0.0001 3 2 0.69
Days before
dismissal home
20 20 0.65 19 20 0.2133
Continuous Infusion Cyclophosphamide and Low Dose
Total Body Irradiation (CICy/ldTBI) As a Conditioning
Regimen for Tandem Autologous Transplant in Multiple
Myeloma
Michael Byrne 1, Helen Leather 2, John R.Wingard 3, JanMoreb 4.
1 Hematology Oncology, University of Florida, Gainesville, FL;
2 HLL Communications, Gainesville, FL; 3 College of Medicine,
Division of Hematology/Oncology, University of Florida,
Gainesville, FL; 4 University of Florida, Gainesville, FL
Multiple myeloma (MM) remains a largely incurable disease
despite recent advances in biologic therapy. Autologous stem
cell transplant (ASCT) is the cornerstone of management yet
morbidity and transplant related mortality (TRM) remain
concerns for patients and physicians alike. Between October
2001 and June 2008, 21 MM patients underwent tandem
ASCT as part of a prospective phase II clinical study. After
initial ASCT, disease response was assessed at post-trans-
plant day 100 (D+100). Patients achieving very good partial
remission (VGPR) were offered maintenance therapy. If
patients achieved partial remission (PR), they were offered
a second autologous transplant (ASCT2) with a novel
conditioning regimen: Continuous IV cyclophosphamide
(CICy) 1500mg/m2/day on day -7 through day -4 followed by
and low dose total body irradiation (ldTBI) given twice dailyat 150 cGy on day -2 and -1. TBI was replaced by melphalan
140 mg/m2 if patients had received prior radiation. Median
duration of neutropenia with CICy/ldTBI was 10 days (range,
8-20). 15 patients (71.4%) developed febrile neutropenia.
After fever, grade 1-2 diarrhea was the most common non-
hematologic adverse event (42.9%). One patient each (4.8%)
developed a limited subdural bleed, pulmonary embolus,
neutropenic colitis, bacterial pneumonia, possible fungal
pneumonia, hemorrhagic cystitis, and septic shock. 19
patients (90.5%) required transfusion support (red blood
cells, platelets, or both) in the post-transplant period. All
patients were alive at D+100 with no treatment related
mortality. Three patients received CICY and melphalan. After
ASCT2, four patients had entered complete remission (CR)
(19.0%), seven achieved VGPR (33.3%), while six (28.6%) had
PR. At 4 years after enrollment of last patient, the median
progression free survival and overall survival was 21 (range,
7-101) and 38 (range, 12-128) months, respectively. In
conclusion, this novel conditioning regimen is safe and
effective alternative to high-dose melphalan, and may be
useful in patients who do not beneﬁt from ﬁrst ASCT using
other conditioning regimens.134
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In autologous hematopoietic stem cell transplantation
(ASCT), G-CSF administered from day +7 until ANC recovery,
expedites ANC recovery and reduces days of hospitalization
by 1-2 days. To determine whether delayed and abbreviated
G-CSF dosage could produce equivalent ANC recovery and
thereby improve cost effectiveness of ASCT for myeloma, we
delayed administration of G-CSF until WBC recovery had
begun and was 0.20/uL. G-CSF so administered was labeled
deferred G-CSF dosing (DGD), Patients in the conventional
dosing group (CGD) received daily doses of 5 mg/kg G-CSF
beginning day +7. The primary and secondary end points are
listed in table-1. The Institutional Review Board approved
retrospective chart analysis
A total of 117 patients with multiple myeloma received
ASCT from January 2005 to September 2012. Of these, 65
patients received DGD and 52 received CGD. Patient, disease,
and transplant-related variables were similar between 2
groups; patients in DGD received a larger dose of CD34+
cells/kg (median 4.49, range¼ 2.49-10.2 vs. median 3.79,
range ¼ 2.61-9.42, p¼ 0.021)
The CGD group received a median of 5 doses of G-CSF,
while the DGD group received, a median of 0 (range 0-5,
P  .0001) G-CSF doses (5mg/kg) when the WBC were
